Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Spectrum Pharma Is Poised to Bounce Back

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Spectrum Pharmaceuticals (NASDAQ: SPPI  ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Spectrum and see what CAPS investors are saying about the stock right now.

Spectrum facts

Headquarters (founded)

Henderson, Nev. (1987)

Market Cap

$475.9 million



Trailing-12-Month Revenue

$211 million


Chairman/CEO Dr. Rajesh Shrotriya
CFO Kurt Gustafson

Return on Equity (average, past 3 years)



$124.4 million / $50.0 million


Biogen Idec
Teva Pharmaceutical

Sources: S&P Capital IQ and Motley Fool CAPS.

Earlier today, CAPS All-Star zzlangerhans succinctly summed up the Spectrum bull case for our community:

Since the big plunge in March, the stock has traded between 7 and 9 as the street apparently awaits a revenue trend. The latest quarterly numbers weren't much of a help, as Zevalin declined while Fusilev and Folotyn ticked up. I'm unenthusiastic about the Marqibo acquisition and the company was very vague about the prospects for apaziquone in the last CC. Probably the brightest light on the horizon is belinostat, although it seems that the prior goal of a late summer NDA submission won't be happening. In short, I'm not expecting great things from this outperform but I see it as a low risk move as the share price dips to the lower end of recent range.

But while you can certainly make big gains in tempting turnaround opportunities, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2609577, ~/Articles/ArticleHandler.aspx, 9/28/2016 6:24:27 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 4:00 PM
SPPI $4.74 Up +0.08 +1.72%
Spectrum Pharmaceu… CAPS Rating: ***
BIIB $314.53 Up +4.71 +1.52%
Biogen CAPS Rating: *****
TEVA $49.47 Down -0.80 -1.59%
Teva Pharmaceutica… CAPS Rating: ****